p300 in prostate cancer proliferation and progression

Although prostate cancer (PCa) is the most frequently diagnosed cancer in males, little is known about the mechanisms involved in its progression. Recent in vitro studies suggest that coactivators of the androgen receptor play an important role in PCa progression. We have shown previously that p300...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2003-11, Vol.63 (22), p.7638-7640
Hauptverfasser: DEBES, Jose D, SEBO, Thomas J, LOHSE, Christine M, MURPHY, Linda M, HAUGEN, De Anna L, TINDALL, Donald J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 7640
container_issue 22
container_start_page 7638
container_title Cancer research (Chicago, Ill.)
container_volume 63
creator DEBES, Jose D
SEBO, Thomas J
LOHSE, Christine M
MURPHY, Linda M
HAUGEN, De Anna L
TINDALL, Donald J
description Although prostate cancer (PCa) is the most frequently diagnosed cancer in males, little is known about the mechanisms involved in its progression. Recent in vitro studies suggest that coactivators of the androgen receptor play an important role in PCa progression. We have shown previously that p300 is involved in androgen receptor transactivation. In the present work, we studied 95 patients with biopsy-proven PCa who underwent prostatectomy as treatment of their tumors between 1995 and 1998. We found that p300 correlated with in vivo proliferation (P = 0.009) as determined by MIB-I expression. Moreover, high levels of p300 in biopsies predicted larger tumor volumes (P < 0.001), extraprostatic extension (P = 0.003), and seminal vesicle involvement (P = 0.002) at prostatectomy, as well as PCa progression after surgery (P = 0.01). Furthermore, we found that the disruption of p300 transcripts through small interfering RNA inhibited PCa cell proliferation both at the basal level and on interleukin 6 stimulation. We conclude that p300 plays an important role in PCa cell proliferation, as well as PCa progression.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71392148</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19234387</sourcerecordid><originalsourceid>FETCH-LOGICAL-h302t-8845ff2ed1986878d5f6db78e27df1a31653753c7a2fd9a557d1e888f8aea6323</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMotlb_guxFbwtJJpPMHqX4BQUvel6mm0RXttuabA_-eyNWPHoanuHhfeE9EnOFQLUzBo_FXEpJNRqnZ-Is5_eCqCSeipkyFsCSngvcgZRVP1a7tM0TT6HqeOxC-uahjyHx1G_Hikf__XlNIefC5-Ik8pDDxeEuxMvd7fPyoV493T8ub1b1G0g91UQGY9TBq4YsOfIYrV87Ctr5qBiURXAInWMdfcOIzqtARJE4sAUNC3H9k1u6P_YhT-2mz10YBh7Ddp9bp6DRytC_omo0GCBXxMuDuF9vgm93qd9w-mx_FynC1UHg3PEQU5mjz38egja2NH4BkwxpJA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19234387</pqid></control><display><type>article</type><title>p300 in prostate cancer proliferation and progression</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>DEBES, Jose D ; SEBO, Thomas J ; LOHSE, Christine M ; MURPHY, Linda M ; HAUGEN, De Anna L ; TINDALL, Donald J</creator><creatorcontrib>DEBES, Jose D ; SEBO, Thomas J ; LOHSE, Christine M ; MURPHY, Linda M ; HAUGEN, De Anna L ; TINDALL, Donald J</creatorcontrib><description>Although prostate cancer (PCa) is the most frequently diagnosed cancer in males, little is known about the mechanisms involved in its progression. Recent in vitro studies suggest that coactivators of the androgen receptor play an important role in PCa progression. We have shown previously that p300 is involved in androgen receptor transactivation. In the present work, we studied 95 patients with biopsy-proven PCa who underwent prostatectomy as treatment of their tumors between 1995 and 1998. We found that p300 correlated with in vivo proliferation (P = 0.009) as determined by MIB-I expression. Moreover, high levels of p300 in biopsies predicted larger tumor volumes (P &lt; 0.001), extraprostatic extension (P = 0.003), and seminal vesicle involvement (P = 0.002) at prostatectomy, as well as PCa progression after surgery (P = 0.01). Furthermore, we found that the disruption of p300 transcripts through small interfering RNA inhibited PCa cell proliferation both at the basal level and on interleukin 6 stimulation. We conclude that p300 plays an important role in PCa cell proliferation, as well as PCa progression.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 14633682</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Acetyltransferases - biosynthesis ; Acetyltransferases - physiology ; Antineoplastic agents ; Biological and medical sciences ; Cell Cycle Proteins - biosynthesis ; Cell Cycle Proteins - physiology ; Cell Division - physiology ; Cell Line, Tumor ; Disease Progression ; Histone Acetyltransferases ; Humans ; Ki-67 Antigen - biosynthesis ; Male ; Medical sciences ; p300-CBP Transcription Factors ; Pharmacology. Drug treatments ; Ploidies ; Prostatectomy ; Prostatic Neoplasms - genetics ; Prostatic Neoplasms - metabolism ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - surgery ; Transcription Factors - physiology ; Tumors</subject><ispartof>Cancer research (Chicago, Ill.), 2003-11, Vol.63 (22), p.7638-7640</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15324648$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14633682$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DEBES, Jose D</creatorcontrib><creatorcontrib>SEBO, Thomas J</creatorcontrib><creatorcontrib>LOHSE, Christine M</creatorcontrib><creatorcontrib>MURPHY, Linda M</creatorcontrib><creatorcontrib>HAUGEN, De Anna L</creatorcontrib><creatorcontrib>TINDALL, Donald J</creatorcontrib><title>p300 in prostate cancer proliferation and progression</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Although prostate cancer (PCa) is the most frequently diagnosed cancer in males, little is known about the mechanisms involved in its progression. Recent in vitro studies suggest that coactivators of the androgen receptor play an important role in PCa progression. We have shown previously that p300 is involved in androgen receptor transactivation. In the present work, we studied 95 patients with biopsy-proven PCa who underwent prostatectomy as treatment of their tumors between 1995 and 1998. We found that p300 correlated with in vivo proliferation (P = 0.009) as determined by MIB-I expression. Moreover, high levels of p300 in biopsies predicted larger tumor volumes (P &lt; 0.001), extraprostatic extension (P = 0.003), and seminal vesicle involvement (P = 0.002) at prostatectomy, as well as PCa progression after surgery (P = 0.01). Furthermore, we found that the disruption of p300 transcripts through small interfering RNA inhibited PCa cell proliferation both at the basal level and on interleukin 6 stimulation. We conclude that p300 plays an important role in PCa cell proliferation, as well as PCa progression.</description><subject>Acetyltransferases - biosynthesis</subject><subject>Acetyltransferases - physiology</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cell Cycle Proteins - biosynthesis</subject><subject>Cell Cycle Proteins - physiology</subject><subject>Cell Division - physiology</subject><subject>Cell Line, Tumor</subject><subject>Disease Progression</subject><subject>Histone Acetyltransferases</subject><subject>Humans</subject><subject>Ki-67 Antigen - biosynthesis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>p300-CBP Transcription Factors</subject><subject>Pharmacology. Drug treatments</subject><subject>Ploidies</subject><subject>Prostatectomy</subject><subject>Prostatic Neoplasms - genetics</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Transcription Factors - physiology</subject><subject>Tumors</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LAzEQhoMotlb_guxFbwtJJpPMHqX4BQUvel6mm0RXttuabA_-eyNWPHoanuHhfeE9EnOFQLUzBo_FXEpJNRqnZ-Is5_eCqCSeipkyFsCSngvcgZRVP1a7tM0TT6HqeOxC-uahjyHx1G_Hikf__XlNIefC5-Ik8pDDxeEuxMvd7fPyoV493T8ub1b1G0g91UQGY9TBq4YsOfIYrV87Ctr5qBiURXAInWMdfcOIzqtARJE4sAUNC3H9k1u6P_YhT-2mz10YBh7Ddp9bp6DRytC_omo0GCBXxMuDuF9vgm93qd9w-mx_FynC1UHg3PEQU5mjz38egja2NH4BkwxpJA</recordid><startdate>20031115</startdate><enddate>20031115</enddate><creator>DEBES, Jose D</creator><creator>SEBO, Thomas J</creator><creator>LOHSE, Christine M</creator><creator>MURPHY, Linda M</creator><creator>HAUGEN, De Anna L</creator><creator>TINDALL, Donald J</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20031115</creationdate><title>p300 in prostate cancer proliferation and progression</title><author>DEBES, Jose D ; SEBO, Thomas J ; LOHSE, Christine M ; MURPHY, Linda M ; HAUGEN, De Anna L ; TINDALL, Donald J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h302t-8845ff2ed1986878d5f6db78e27df1a31653753c7a2fd9a557d1e888f8aea6323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Acetyltransferases - biosynthesis</topic><topic>Acetyltransferases - physiology</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cell Cycle Proteins - biosynthesis</topic><topic>Cell Cycle Proteins - physiology</topic><topic>Cell Division - physiology</topic><topic>Cell Line, Tumor</topic><topic>Disease Progression</topic><topic>Histone Acetyltransferases</topic><topic>Humans</topic><topic>Ki-67 Antigen - biosynthesis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>p300-CBP Transcription Factors</topic><topic>Pharmacology. Drug treatments</topic><topic>Ploidies</topic><topic>Prostatectomy</topic><topic>Prostatic Neoplasms - genetics</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Transcription Factors - physiology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DEBES, Jose D</creatorcontrib><creatorcontrib>SEBO, Thomas J</creatorcontrib><creatorcontrib>LOHSE, Christine M</creatorcontrib><creatorcontrib>MURPHY, Linda M</creatorcontrib><creatorcontrib>HAUGEN, De Anna L</creatorcontrib><creatorcontrib>TINDALL, Donald J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DEBES, Jose D</au><au>SEBO, Thomas J</au><au>LOHSE, Christine M</au><au>MURPHY, Linda M</au><au>HAUGEN, De Anna L</au><au>TINDALL, Donald J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>p300 in prostate cancer proliferation and progression</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>2003-11-15</date><risdate>2003</risdate><volume>63</volume><issue>22</issue><spage>7638</spage><epage>7640</epage><pages>7638-7640</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>Although prostate cancer (PCa) is the most frequently diagnosed cancer in males, little is known about the mechanisms involved in its progression. Recent in vitro studies suggest that coactivators of the androgen receptor play an important role in PCa progression. We have shown previously that p300 is involved in androgen receptor transactivation. In the present work, we studied 95 patients with biopsy-proven PCa who underwent prostatectomy as treatment of their tumors between 1995 and 1998. We found that p300 correlated with in vivo proliferation (P = 0.009) as determined by MIB-I expression. Moreover, high levels of p300 in biopsies predicted larger tumor volumes (P &lt; 0.001), extraprostatic extension (P = 0.003), and seminal vesicle involvement (P = 0.002) at prostatectomy, as well as PCa progression after surgery (P = 0.01). Furthermore, we found that the disruption of p300 transcripts through small interfering RNA inhibited PCa cell proliferation both at the basal level and on interleukin 6 stimulation. We conclude that p300 plays an important role in PCa cell proliferation, as well as PCa progression.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>14633682</pmid><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 2003-11, Vol.63 (22), p.7638-7640
issn 0008-5472
1538-7445
language eng
recordid cdi_proquest_miscellaneous_71392148
source MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals
subjects Acetyltransferases - biosynthesis
Acetyltransferases - physiology
Antineoplastic agents
Biological and medical sciences
Cell Cycle Proteins - biosynthesis
Cell Cycle Proteins - physiology
Cell Division - physiology
Cell Line, Tumor
Disease Progression
Histone Acetyltransferases
Humans
Ki-67 Antigen - biosynthesis
Male
Medical sciences
p300-CBP Transcription Factors
Pharmacology. Drug treatments
Ploidies
Prostatectomy
Prostatic Neoplasms - genetics
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - pathology
Prostatic Neoplasms - surgery
Transcription Factors - physiology
Tumors
title p300 in prostate cancer proliferation and progression
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T00%3A43%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=p300%20in%20prostate%20cancer%20proliferation%20and%20progression&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=DEBES,%20Jose%20D&rft.date=2003-11-15&rft.volume=63&rft.issue=22&rft.spage=7638&rft.epage=7640&rft.pages=7638-7640&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E19234387%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19234387&rft_id=info:pmid/14633682&rfr_iscdi=true